Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX by Wulffraat NM, Rademaker C, Sinnema G, Bulatović M, Verkaaik M

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis by Heijstek MW, Berbers GAM, van Gageldonk PGM, Uiterwaal CSP, Wulffraat NM

Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis by Heijstek MW, Wulffraat NM, Eken Y, Pluijm SMF, Rademaker CMA, de Jonge R

Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases by van der Klis F, Berbers G, Tacke C, Scherpenisse M, Groot N, Heijstek MW, Wulffraat NM

Mesenchymal stem cells and JIA by Slaper-Cortenbach I, Martens AC, Prakken BJ, Kuis W, Hofhuis F, de Roock S, Swart JF, Wulffraat NM

Etanercept in juvenile idiopathic arthritis: Who will benefit? by van den Berg JM, Swart JF, Dolman KM, Gorter SL, Koopman-Keemink Y, Twilt M, Hoppenreijs EPAH, ten Cate R, Armbrust W, Prince FHM, Otten MH, Wulffraat NM, van Rossum MAJ, van Suijlekom-Smit LWA

Preclinical aortic atherosclerosis in adolescents with chronic disease by Ververs, FA, Eikendal, ALM, Kofink, D, Nuboer, R, Westenberg, JJM, Hovenkamp, GT, Kemps, JJA, Coenen, ICJ, Daems, JJN, Claus, LR, Ju, Y, Wulffraat, NM, van der Ent, CK, Monaco, C, Boes, M, Leiner, T, Grotenhuis, HB, Schipper, HS

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a... by McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, Kallinich T, Erguven M, Berkun Y, Constantin T, Quartier P, Horneff G, Brunner H, Ruperto N, Lheritier K, Preiss R, Tseng L, Martini A, Lovell DJ